Homocysteine in coronavirus disease (COVID-19): a systematic literature review

Abstract Objectives Coronavirus disease 2019 (COVID-19) is a life-threatening infectious disorder characterized by a sustained prothrombotic state. Since homocysteine is a potential biomarker of thrombotic diseases, the aim of this article is to provide an updated overview on the possible role played by hyperhomocysteinemia in influencing an unfavorable COVID-19 progression. Methods We carried out an electronic search in Medline (PubMed interface) using the keywords (“COVID-19” OR “SARS-CoV-2”) AND “homocysteine”, between 2019 and the present time, with no language restrictions, to identify all articles which explored the concentration of homocysteine in COVID-19 patients with or without unfavorable disease progression. Results Three studies, totaling 694 hospitalized COVID-19 patients, were included in our systematic review. Overall, the differences between the mean homocysteine values in non-severe vs. severe COVID-19 patients were always positive (i.e., 15.1%, 24.1% and 22.8%, generating a positive weight mean difference of 1.75 μmol/L (95%CI, 1.26–2.25 μmol/L; p=0.011), which translates into a cumulative difference of approximately ∼1.2 μmol/L. Conclusions Despite the limited evidence that has been garnered so far, increased homocysteine levels may be a potentially useful marker for predicting the risk of unfavorable progression in patients with COVID-19.

[1]  T. Matsha,et al.  Methylenetetrahydrofolate (MTHFR), the One-Carbon Cycle, and Cardiovascular Risks , 2021, Nutrients.

[2]  D. Jacobsen.  Homocysteine and vitamins in cardiovascular disease. , 1998, Clinical chemistry.

[3]  J. Vandenbroucke,et al.  The Leiden Thrombophilia Study (LETS) , 1997, Thrombosis and Haemostasis.

[4]  Huiying Zhao,et al.  Epigenetic factors in atherosclerosis: DNA methylation, folic acid metabolism, and intestinal microbiota. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[5]  K. Robinson,et al.  Homocysteine and renal disease. , 2000, Seminars in thrombosis and hemostasis.

[6]  S. Mirsadraee,et al.  Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review , 2021, Journal of Thrombosis and Thrombolysis.

[7]  Ying Lü,et al.  Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients , 2020, Aging.

[8]  G. Lippi,et al.  COVID-19: unravelling the clinical progression of nature’s virtually perfect biological weapon , 2020, Annals of translational medicine.

[9]  D. Gommers,et al.  Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis , 2020, Thrombosis Research.

[10]  H. Kwaan.  Coronavirus Disease 2019: The Role of the Fibrinolytic System from Transmission to Organ Injury and Sequelae , 2020, Seminars in Thrombosis and Hemostasis.

[11]  G. Lippi,et al.  Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis , 2021, Seminars in Thrombosis and Hemostasis.

[12]  M. Ramakers,et al.  High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients , 2020, Journal of Thrombosis and Haemostasis.

[13]  A. Coppola,et al.  Homocysteine (Hcy) assessment to predict outcomes of hospitalized Covid-19 patients: a multicenter study on 313 Covid-19 patients , 2021, Clinical chemistry and laboratory medicine.

[14]  H. Krumholz,et al.  Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research , 2020, Thrombosis and Haemostasis.

[15]  Giuseppe Lippi,et al.  Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm , 2020, Annals of translational medicine.

[16]  E. Lonn,et al.  Homocysteine-Lowering Therapy and Risk for Venous Thromboembolism , 2007, Annals of Internal Medicine.

[17]  Giuseppe Lippi,et al.  Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis , 2020, Clinica Chimica Acta.

[18]  S. Schulman.  Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism , 2020, Seminars in Thrombosis and Hemostasis.

[19]  J. Thachil,et al.  Coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[20]  A. Hvas,et al.  Platelets in Coronavirus Disease 2019 , 2020, Seminars in Thrombosis and Hemostasis.

[21]  D. Leaf,et al.  COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection , 2020, Blood.

[22]  Recai Aci,et al.  Homocysteine as a marker for predicting disease severity in patients with COVID-19. , 2022, Biomarkers in medicine.